Antibody Reduces Recurrence in HER2-Positive Breast Cancer

Study by KPSOM faculty study finds significant improvement in survival rates

August 31, 2023

KPSOM Professor of Health Systems Science Reina Haque

KPSOM Professor of Health Systems Science Reina Haque

Reina Haque, PhD, MPH, Kaiser Permanente Bernard J. Tyson School of Medicine (KPSOM) Professor of Health Systems Science, has coauthored a study highlighting the positive impact of trastuzumab on reducing recurrence risk in HER2-positive breast cancer. Trastuzumab, a humanized monoclonal antibody, has shown significant improvements in disease-free survival and overall survival rates. The study emphasizes the major treatment advances trastuzumab brings to patients.

The research explores outcomes beyond clinical trial settings and reveals that despite trastuzumab therapy, a cumulative risk of subsequent breast cancer events remains, underlining the importance of clinicians considering newer HER2-targeted therapy options for long-term prevention. The study provides valuable insights into real-world outcomes for women with HER2-positive breast cancer, offering crucial information for improving clinical practices.

Read the article here .